This is a translation of the original article in Portuguese. Read the original (Português).
A new drug for pancreatic cancer, daraxonrasib, made tumors disappear completely on scans in 8.2% of patients in an early study. Combined with chemotherapy, the medicine also stopped tumor growth in 90.2% of participants. The data were released by the British newspaper The Times.
The study enrolled 61 patients and was presented in Barcelona, Spain. Researchers are calling for further trials before the treatment is adopted by Britain’s National Health Service (NHS).
Pancreatic cancer is one of the tumor types with the lowest survival rates. For that reason, any advance draws the attention of patients and families in many countries, including Brazil.
The numbers call for caution. An early study usually has few participants and generally serves to assess whether a treatment is safe and shows signs of effectiveness. The results still need to be confirmed in larger trials that compare the drug with treatments already in use, before any approval.
The 90.2% figure means the disease stopped growing, which is not the same as a cure. The complete disappearance of tumors on scans, seen in 8.2% of cases, is the finding that draws the most attention, but it applies to a small group of patients.
In Brazil, a new medicine only reaches the Unified Health System (SUS) after going through steps: first approval by Brazil’s health regulator (Anvisa), then an assessment for incorporation into the public system. The responsible agencies have yet to detail what this path would look like for daraxonrasib, and there is no forecast of when it could be available in the country.
Access to cutting-edge cancer drugs
Access to advanced cancer medicines is a recurring issue in the country, since new treatments tend to appear first in the private sector or through court orders, before any eventual incorporation into the SUS.
Reporting from The Times (p. 13, Barcelona (Espanha)).
Deixe um comentário